Angermann, C., Sehner, S., Gerhardt, L. M. S., Santos-Gallego, C. G., Requena-Ibanez, J. A., Zeller, T., . . . Badimon, J. J. (2025). Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: The EMPATROPISM-FE trial : clinical research : heart failure and cardiomyopathies. European heart journal, 46(16), . https://doi.org/10.1093/eurheartj/ehae917
Chicago Style (17th ed.) CitationAngermann, Christiane, et al. "Anaemia Predicts Iron Homoeostasis Dysregulation and Modulates the Response to Empagliflozin in Heart Failure with Reduced Ejection Fraction: The EMPATROPISM-FE Trial : Clinical Research : Heart Failure and Cardiomyopathies." European Heart Journal 46, no. 16 (2025). https://doi.org/10.1093/eurheartj/ehae917.
MLA (9th ed.) CitationAngermann, Christiane, et al. "Anaemia Predicts Iron Homoeostasis Dysregulation and Modulates the Response to Empagliflozin in Heart Failure with Reduced Ejection Fraction: The EMPATROPISM-FE Trial : Clinical Research : Heart Failure and Cardiomyopathies." European Heart Journal, vol. 46, no. 16, 2025, https://doi.org/10.1093/eurheartj/ehae917.